DUBLIN – Mina Therapeutics Ltd. continues to make progress in its long-term ambition to establish small activating RNA (saRNA) as a new therapeutic modality. The biotech has now entered a multitarget research collaboration with Eli Lilly and Co., in which it is receiving $25 million up front and up to $245 million in development and commercial milestones per product.